Latest News

Columbia Financial (CLBK) is forecasting annual revenue growth of 14.5%, surpassing the broader US market’s 10.1% projected rate. Earnings are expected to jump by 54.2% each year, well ahead of the 15.5% annual growth seen across the US market. Despite these upbeat forecasts, net profit margins have slipped to 7.4% from last year’s 8%, and the company’s earnings have fallen 33.4% per year on average over the past five years. With strong future growth prospects but currently compressed...

Rexford Industrial Realty (REXR) reported net profit margins of 32.9%, up from 29.3% last year, highlighting robust profitability. While the company’s earnings have grown at an impressive 29.3% per year over the past five years, growth cooled to 23.8% in the most recent year. Future projections indicate a 1.6% annual earnings decline and 5.1% revenue growth, which lags behind the broader US market. Results were buoyed by an $80.1 million one-off gain, and the shares currently trade at $43.41,...

Thinking about what your next move with Heineken stock should be? You are not alone. Whether you are eyeing that distinctive green bottle on store shelves or watching its ticker on your favorite trading app, Heineken has been turning heads lately. After what felt like a sluggish 2023 for the Dutch brewing giant, the stock has started 2024 with fresh momentum. Just this past week, Heineken shares climbed 4.9%, extending a 7.0% gain over the past month, and even year-to-date, it is modestly up...

Pentair (PNR) reported a net profit margin of 15.8%, slightly down from 16.3% last year. Recent earnings growth turned negative following a five-year annual average growth rate of 9.6%. Looking ahead, earnings are forecast to grow at around 12% per year. However, this pace is slower than both the broader US market and the company's own revenue growth projections. With high quality reported earnings and the stock trading below an estimated fair value, investors are weighing slower near-term...

Washington Trust Bancorp (WASH) reported ongoing losses, with net losses worsening at a 35.3% annual rate over the past five years. Despite the negative net profit margin and declining recent earnings, the company is forecast to deliver a substantial turnaround, with expected earnings growth of 81.26% per year and revenue growth of 21.8%, both outpacing the broader US market. Shares currently trade at $27.55, which is below the estimated fair value of $36.94 per share. Investors remain...

Community Financial System (CBU) posted a current net profit margin of 26.4%, up from last year’s 23.5%, while earnings growth for the year hit 23.7%. Over the past five years, the company’s earnings averaged 0.6% annual growth, and forecasts now call for earnings to rise 18.31% per year, ahead of the broader US market. Running a Price-To-Earnings ratio of 14.5x, CBU trades at a premium to the US Banks industry but still sits below its peer average. With no identified risks and ongoing profit...

Valmont Industries (VMI) reported net profit margins of 6.3%, down from 7.3% last year, as current results reflect the impact of a one-off loss of $101.4 million over the last twelve months. The company is forecasting earnings growth of 16.2% per year, outpacing the US market’s 15.5% average, while revenue is expected to grow 3.5% annually compared to the industry’s 10.1%. With these projections, investors are likely to focus on Valmont’s path to regaining margin strength and monitoring its...

Acme United (ACU) reported a net profit margin of 5.3%, marking a decline from last year’s 10.1%. Negative earnings growth over the past year contrasts with its five-year average annual earnings increase of 9.4%. With revenue forecast to rise just 4.8% per year and earnings expected to fall 15.9% annually over the next three years, investors are scrutinizing the company’s weaker margins and muted prospects. The P/E ratio stands at 13.9x and the share price is $37.75, both below industry and...

First United (FUNC) reported standout earnings growth of 54.4% over the past year, far outpacing its 5-year average of 5.3% per year. Net profit margins reached 29.8%, rising from 22.7% in the prior year, while shares are currently trading at $36.98, well below an estimated fair value of $68.47. With only one minor risk flagged and multiple rewards highlighted, including high-quality past earnings, expanding profit and revenue, and a strong value profile, the latest results point to improved...

Quest Diagnostics (DGX) posted a 13% rise in earnings over the past year, reversing a five-year stretch where earnings declined an average 19.9% annually. Net profit margins increased to 9%, compared to 8.9% last year, and the company is now projected to grow earnings at 9.8% per year going forward. For investors, the key takeaway is a clear shift toward profitability. However, with future growth expectations trailing the broader US market, sentiment may remain mixed. See our full analysis...

Home Bancorp (HBCP) saw earnings rise by 22.6% over the past year, pushing net profit margin up to 30.5% from 27.8% a year earlier, even as revenue is expected to dip at an annual rate of -0.5% over the next three years. With shares trading at $55.25, well below the estimated fair value of $113.99 and at a Price-to-Earnings ratio of 9.8x, lower than key industry benchmarks, investors are seeing clear value signals. Strong profitability and an attractive dividend round out a quarter in which...

PACCAR (PCAR) delivered strong earnings growth, with profits rising at an annual rate of 24.2% over the past five years. While net profit margins dipped to 9.9% from last year's 14.1%, earnings are now forecast to grow at 18.1% per year, outpacing the broader US market. This rapid earnings growth, combined with a price-to-earnings ratio of 17.1x below industry and peer averages, sets the stage for continued optimism, though investors are watching the slip in margins closely. See our full...

Perspective Therapeutics revealed updated interim results from its Phase 1/2a trial of [212Pb]VMT-alpha-NET at ESMO Congress 2025, which sparked a sharp drop in the company’s share price as investors digested the latest efficacy signals. See our latest analysis for Perspective Therapeutics. This latest clinical trial update comes after a challenging year for Perspective Therapeutics. Following a brief rally in anticipation of new data, the 1-day share price return slipped by 2.5%, and the...

Tose Co., Ltd.'s ( TSE:4728 ) earnings announcement last week was disappointing for investors, despite the decent...

Greene County Bancorp (GCBC) delivered robust results in its most recent earnings, with net income growing by 25.7% over the last year and an annualized growth rate of 4.8% over the past five years. Profit margins expanded to 42.4%, up from 38.6% a year ago, reflecting stronger operational efficiency and profitability. As investors assess these figures, the company’s valuation metrics, attractive dividend, and consistent growth profile come into focus, setting the stage for a balanced but...

BOK Financial (BOKF) delivered robust results, with earnings climbing 14.2% over the past year, far surpassing its 5-year annual average growth rate of just 0.2%. Net profit margins reached 25.2%, an improvement over last year’s 23.2%, and the company is noted for high-quality earnings. While the current share price of $106.52 trails some fair value estimates, the high margin profile and steady operational performance set the tone for investor expectations as the market weighs slower...

ServisFirst Bancshares (SFBS) posted revenue growth forecast at 15.4% per year, outpacing the US market’s 10.1% trend, while earnings growth is projected at an even stronger 17.25% annually. Recent annual earnings growth came in at 25.1%, well above the company’s five-year average of 5.1% per year, and profit margins expanded to 51.3% from last year’s 47.6%. With earnings quality described as high, these numbers underscore momentum and profitability. Investor sentiment will likely weigh the...

West Coast Community Bancorp (WCCB) posted a net profit margin of 32.1% for the latest period, down from 40.9% a year earlier. Earnings grew 3.2% year-over-year, falling short of the company’s five-year average growth rate of 15.9% per year, signaling a slowdown. Despite this moderation, WCCB has a notable record of high-quality earnings and substantial profit growth, which continues to underscore operational strength in today’s market. See our full analysis for West Coast Community...

On October 13, 2025, SQ Innovation received FDA approval for Lasix ONYU, a combination product featuring Gerresheimer’s proprietary on-body infusor for at-home subcutaneous drug delivery in select congestive heart failure patients. This milestone showcases Gerresheimer’s technological capabilities in advanced drug delivery devices and highlights its growing position as a full-service partner to pharmaceutical companies embracing home-based care. Next, we’ll explore how the FDA-backed rollout...

Artiva Biotherapeutics recently announced that the FDA has granted Fast Track Designation to its AlloNK (AB-101) therapy in combination with rituximab for the treatment of refractory rheumatoid arthritis, marking a first for deep B-cell depleting therapies in this indication. This development highlights Artiva's focus on addressing a large unmet need in autoimmune disease with an outpatient-ready, community-administered cellular therapy. We'll explore how Fast Track status for AlloNK and...

Sartorius Aktiengesellschaft has recently reported its third quarter and nine-month results for 2025, highlighted by increased sales to €843.2 million and a rise in net income to €43.8 million, also raising its full-year 2025 financial guidance after considering the MATTEK acquisition and market conditions. An interesting point is Sartorius' management specifically sharpened its guidance, factoring in strong year-to-date performance, new tariffs, acquisition impact, and comparisons to the...

Key Insights Significantly high institutional ownership implies Resonac Holdings' stock price is sensitive to their...

JNTC Co., Ltd. ( KOSDAQ:204270 ), might not be a large cap stock, but it received a lot of attention from a substantial...

Guan Chong Berhad ( KLSE:GCB ) shareholders should be happy to see the share price up 13% in the last week. But that...